Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial

Lancet (London, England) · 2026 Nov 9 · Bozkurt B, le Roux CW, Wharton S et

By Maren Holt · Senior Reporter, GLP-1

Nov 8 19:00 ETSource: Lancet (London, England)

From the source

Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial
Lancet (London, England) · 2026 Nov 9 · Bozkurt B, le Roux CW, Wharton S et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/43003106/